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Abstract 18 
 19 
The initiation of innate immune responses against pathogens relies on the activation of pattern-recognition 20 
receptors (PRRs) and corresponding intracellular signalling cascades. To avoid inappropriate or excessive 21 
activation of PRRs, these responses are tightly controlled. Cullin-RING E3 ubiquitin ligases (CRLs) have 22 
emerged as critical regulators of many cellular functions including innate immune activation and 23 
inflammation. CRLs form multiprotein complexes in which a Cullin protein acts as a scaffold and recruits 24 
specific adaptor proteins, which in turn recognise specific substrate proteins for ubiquitylation, hence 25 
providing selectivity. CRLs are divided into 5 main groups, each of which uses a specific group of adaptor 26 
proteins. Here, we systematically depleted all predicted substrate adaptors for the CRL5 family (the so-27 
called SOCS-box proteins) and assessed the impact on the activation of the inflammatory transcription 28 
factor NF-κB. Depletion of SPSB1 resulted in a significant increase in NF-κB activation, indicating the 29 
importance of SPSB1 as an NF-κB negative regulator. In agreement, overexpression of SPSB1 suppressed 30 
NF-κB activity in a potent, dose-dependent manner in response to various agonists. Inhibition by SPSB1 31 
was specific to NF-κB, because other transcription factors related to innate immunity and interferon (IFN) 32 
responses such as IRF-3, AP-1 and STATs remained unaffected by SPSB1. SPSB1 suppressed NF-κB 33 
activation induced via multiple pathways including Toll-like receptors and RNA and DNA sensing 34 
adaptors, and required the presence of its SOCS-box domain. To provide mechanistic insight, we examined 35 
phosphorylation and degradation of the inhibitor of κB (IκBα) and p65 translocation into the nucleus. Both 36 
remained unaffected by SPSB1, indicating that SPSB1 exerts its inhibitory activity downstream, or at the 37 
level, of the NF-κB heterodimer. In agreement with this, SPSB1 was found to co-precipitate with p65 after 38 
over-expression and at endogenous levels. Additionally, A549 cells stably expressing SPSB1 presented 39 
lower cytokine levels including type I IFN in response to cytokine stimulation and virus infection. Taken 40 
together, our results reveal novel regulatory mechanisms in innate immune signalling and identify the 41 
prominent role of SPSB1 in limiting NF-κB activation. Our work thus provides insights into inflammation 42 
and inflammatory diseases and new opportunities for the therapeutic targeting of NF-κB transcriptional 43 
activity.  44 
 45 
  46 
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Introduction 47 
 48 
Few transcription factors have such crucial roles in the induction of innate immune and inflammatory 49 
responses as the NF-κB family (Ghosh and Hayden, 2012). NF-κB is central in the pathogenesis of multiple 50 
inflammatory disorders including those in the airway by inducing the production of pro-inflammatory 51 
cytokines such as interleukins (IL) and tumour necrosis factors (TNF). In addition, NF-κB contributes to 52 
the expression of type I interferon (IFN) in association with the IFN regulatory factors (IRF)-3/7, and the 53 
activator protein (AP)-1. Once secreted IFN triggers the production of hundreds of IFN-stimulated genes 54 
(ISG) via the Janus-associated kinase (JAK)-signal transducers and activators of transcription (STAT) 55 
signalling pathway, which confer an antiviral state to surrounding cells. NF-κB thus also impacts on the 56 
host antiviral response.  57 
 58 
In the classical NF-κB pathway, the NF-κB p65 and p50 heterodimer is held inactive in the cytosol bound 59 
to the inhibitor of κB (IκB). Degradation of IκBα and subsequent release of NF-κB can be induced by 60 
multiple cytokine receptors and pattern-recognition receptors (PRRs) including Toll-like receptors (TLRs) 61 
that recognise viral and bacterial nucleic acids and lipids. Engagement of TNF-α with its receptor on the 62 
cell surface induces a signalling cascade that involves the TNFR-associated factor 2 (TRAF-2), whereas 63 
signalling downstream of TLRs and IL-1R employs TRAF-6. Activation of these signalling pathways 64 
induces the formation of polyubiquitin chains that act as a scaffold for the recruitment of the transforming 65 
growth factor (TGF)β-activated kinase (TAK)-1 complex via its TAK-1-binding proteins (TAB)-2/3 and 66 
the IκB kinase (IKK) complex (Chen, 2012;Clark et al., 2013). Once both complexes are recruited, TAK-1 67 
catalyses the phosphorylation and activation of the IKK catalytic subunits (IKK-α and IKK-β), which 68 
phosphorylate IκB (Traenckner et al., 1995). Phosphorylated IκBα is recognised by a Cullin-RING 69 
ubiquitin ligase (CRL) complex containing Cullin-1 and the F-box protein β-transducin repeat containing 70 
protein (β-TrCP), also known as FBXW11 (Cenciarelli et al., 1999;Winston et al., 1999), that mediates its 71 
ubiquitylation and proteasome-dependent degradation (Yaron et al., 1998). The essential role of the β-72 
TrCP-containing CRL1 complex in NF-κB activation is highlighted by the long list of viruses that 73 
antagonise its function including poxviruses (Mansur et al., 2013;Neidel et al., 2015), rotaviruses (Morelli 74 
et al., 2015), and the human immunodeficiency virus (Margottin et al., 1998).  75 
 76 
Nuclear p65 associates with transcriptional activators such as p300/CBP and general transcription 77 
machinery and drives the expression of genes containing NF-κB responsive elements. A plethora of post-78 
translational modifications (PTM) affecting p65 (i.e. phosphorylation, acetylation, methylation, 79 
ubiquitylation, etc.) modulate the potency of this response and its selectivity towards specific NF-κB-80 
dependent genes (Huang et al., 2010). These modifications are critical in fine-tuning the transcriptional 81 
activity of NF-κB. 82 
 83 
Ubiquitylation of a protein involves its covalent attachment of ubiquitin moieties that can subsequently be 84 
ubiquitylated to form chains (Komander and Rape, 2012). CRL are the largest family of ubiquitin ligases 85 
and are characterised by the presence of a Cullin (Cul) protein acting as a scaffold (Petroski and Deshaies, 86 
2005). There are 5 major Cul and hence CRL (CRL1-5) families, all of which share similar architecture but 87 
recruit and target different subsets of substrates. CRL substrate recognition is directed by specific substrate 88 
receptor subunits. CRL5 complexes employ substrate receptor proteins containing the suppressor of 89 
cytokine signalling (SOCS) motif (Kamura et al., 2004;Yu et al., 2004). The SOCS box in these adaptor 90 
proteins mediates interaction with the Elongin B/C proteins that associate with Cul-5, effectively forming 91 
a CRL5 complex also known as ECS (Elongin B/C-Cul5-SOCS-box protein). Analogous to F-box proteins 92 
and CRL1 complexes, the SOCS-box domain appears in combination with other protein-protein interaction 93 
domains including Ankyrin, SPRY and Src homology domains (Hilton et al., 1998;Kohroki et al., 2005). 94 
These domains are responsible for the recognition of substrates via unique signatures in the primary amino 95 
acid sequence or specific PTMs, but in many cases these remain to be elucidated. The most studied CRL5 96 
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complex is that formed by the so-called SOCS proteins (SOCS1-7), which target JAKs and act as potent 97 
inhibitors of JAK-STAT signalling (Linossi et al., 2013). SOCS proteins are therefore potent negative 98 
regulators of cytokine signaling, particularly IFN, suggesting that other CRL5 adaptors may evolved similar 99 
functions suppressing innate immune activation. 100 
 101 
Here, we have performed an RNAi-based screen to assess the role of CRL5 adaptors in NF-κB signalling. 102 
Our work has identified several molecules positively and negatively regulating the pathway, in particular 103 
the SPRY and SOCS-box containing protein (SPSB)-1. Depletion of SPSB1 resulted in enhanced NF-κB 104 
activation and cytokine expression, whereas its overexpression suppressed NF-κB responses triggered by 105 
cytokines as well as viruses. Our results indicate that SPSB1 associate with p65 but does not block its 106 
translocation, which suggests that it targets released p65. SPSB1 is known to target the inducible nitric 107 
oxide synthase (iNOS) (Lewis et al., 2011;Nishiya et al., 2011) and has been linked with several pathways 108 
related to cancer, but no direct role for SPSB1 in controlling NF-κB activation has been reported. Our data 109 
therefore define another function for SPSB1 in innate immunity and inflammation and reveal novel 110 
regulatory mechanisms modulating NF-κB activation.  111 
 112 
Results 113 
 114 
Identification of SPSB1 as a negative regulator of NF-κB signalling 115 
 116 
In order to identify novel members of CRLs that act as regulators of the NF-κB pathway, we set up an assay 117 
to systematically deplete CRL genes in A549 cells stably expressing the firefly luciferase gene under the 118 
control of a synthetic NF-κB promoter (Sumner et al., 2014). These cells were transfected with a 119 
commercial library of siRNA designed to target all predicted human SOCS-box containing proteins (Table 120 
S1). Each gene was targeted by a pool of four individual small interfering (si)RNA duplexes. After 72 h the 121 
cells were treated with IL-1β and the luciferase activity was measured 6 h later. In a similar experiment, the 122 
viability of the cells transfected with the siRNA pools was measured. The screen was performed twice and 123 
included a non-targeting control (NTC) siRNA pool and a siRNA pool targeting β-TrCP, the CRL1 adaptor 124 
required for NF-κB activation. Each screen included triplicate replicates for each sample, and the data were 125 
normalised to the NTC (Fig. 1A). As expected knock-down of β-TrCP resulted in a decrease in NF-κB 126 
activation. Amongst the 38 siRNA pools tested only SPSB1 depletion consistently resulted in a significant 127 
increase (~240%) in NF-κB activity without showing major changes in the viability of the cells (arbitrary 128 
cut-off of >75 %), suggesting that this protein has a prominent role in controlling NF-κB signalling.  129 
 130 
To validate these initial data, we deconvolved the pool targeting SPSB1 and transfected the 4 different 131 
siRNA separately to test their effect on NF-κB activation under the same conditions used before, including 132 
NTC and β-TrCP siRNA controls. Two siRNA (#2 and #4) replicated the data observed for the pool (Fig. 133 
1B) and this represented an H-score of 0.5, a value that supported the results from the first screen (Bhinder 134 
and Djaballah, 2012). We then performed stable depletion of SPSB1 via short hairpin (sh)RNA 135 
transduction. Depletion of SPSB1 in the shSPSB1 cells as compared to the NTC shCtl cells was confirmed 136 
by immunoblotting (Fig. 1C). These cell lines were then used to further confirm the impact of SPSB1 on 137 
NF-κB signalling. The cells were treated with IL-1β for 6 h and the mRNA levels of the cytokines iNOS 138 
and IL-6 were examined by quantitative PCR. Treatment with IL-1β resulted in 63- and 190-fold increase 139 
of iNOS and of IL-6 expression in the control A549 cell line, respectively. In the absence of SPSB1, this 140 
same treatment induced a significantly higher expression of both iNOS and IL-6 (150 and 660 fold, 141 
respectively) and this was statistically significant (Fig. 1D and 1E). Taken together, these data identified 142 
SPSB1 as a novel negative regulator of the NF-κB pathway, with its depletion resulting in higher expression 143 
of pro-inflammatory NF-κB-dependent genes.  144 
 145 
SPSB1 inhibits NF-κB, but not IRF-3, AP-1, or STAT activation 146 
 SPSB1 inhibition of NF-κB signalling 
4 
 147 
To study the function of SPSB1, its sequence was cloned into a mammalian expression vector containing 3 148 
copies of the FLAG epitope at the N terminus. SPSB1 was then tested for its ability to inhibit NF-κB 149 
activation. HEK293T cells were transfected with a reporter expressing firefly luciferase under the control 150 
of the canonical NF-κB promoter, a control reporter expressing renilla luciferase, and either SPSB1 or the 151 
corresponding empty vector (EV). After 24 h, the NF-κB pathway was stimulated with IL-1β or TNF-α for 152 
a further 6 h. The ratio of firefly and renilla luciferase activities was calculated and plotted as a fold increase 153 
over the non-stimulated EV-transfected condition. The same cell lysates were also examined by 154 
immunoblotting to determine SPSB1 expression levels. Stimulation by IL-1β or TNF-α triggered >20- and 155 
>60-fold increase, respectively, in reporter activity in EV-transfected samples. Expression of SPSB1 156 
reduced the activation induced by IL-1β (Fig. 2A) and TNF-α (Fig. 2B) in a dose-response and statistically 157 
significant manner.  158 
 159 
To assess the specificity of SPSB1 in controlling innate immune responses, the activation of the IRF, 160 
mitogen-activated protein kinase (MAPK)/AP-1, and JAK-STAT signalling pathways was examined using 161 
reporter gene assays specific for each pathway. To determine the impact of SPSB1 on the IRF-3 signalling 162 
pathway, cells were transfected and subsequently infected with Sendai virus (SeV), a strong inducer of IRF-163 
3 (Rehwinkel et al., 2010). The infection induced a 13-fold activation in the control cells. This was blocked 164 
by the vaccinia virus (VACV) protein C6, a known inhibitor of IRF-3 signalling (Unterholzner et al., 2011), 165 
but remained unaffected by SPSB1 (Fig. 2C). Stimulation of the MAPK pathway was achieved by 166 
incubation with phorbol 12-myristate 13-acetate (PMA) for 24 h, which induced a 4-fold activation in the 167 
EV-transfected cells. This response was downregulated by the VACV protein A49 (Torres et al., 2016), but 168 
not by SPSB1 (Fig. 2D). Finally, to address whether SPSB1 was able to impact signalling triggered by IFN 169 
via the JAK/STAT pathway, cells were transfected with a reporter expressing luciferase under the control 170 
of the IFN stimulating response element (ISRE) and stimulated with IFN-β. This treatment resulted in a 15-171 
fold induction in both EV- as well as SPSB1-transfected cells, indicating that SPSB1 did not affect 172 
JAK/STAT signalling (Fig. 2E). The above demonstrates that SPSB1 is not a general transcriptional 173 
modulator and specifically regulates NF-κB responses.  174 
 175 
SPSB1 inhibits NF-κB activation downstream of multiple effectors and requires its SOCS 176 
domain 177 
 178 
We then aimed to gain further insights into SPSB1 regulation of NF-κB signalling using different 179 
approaches. First, we performed luminescence-based mammalian interactome mapping (LUMIER) assays 180 
(Barrios-Rodiles et al., 2005;Maluquer de Motes et al., 2011;Maluquer de Motes et al., 2014) to examine 181 
possible interactions between SPSB1 and a number of molecules operating at multiple levels downstream 182 
of the IL-1R signalling cascade (Fig. 3A). SPSB1 was initially found to self-associate (Fig. S1). This 183 
property was used to ensure that the fusion of SPSB1 with renilla luciferase (Rluc) did not affect its 184 
expression or folding. FLAG-SPSB1 was then co-transfected with Rluc fusions for either TRAF-6, TAK-185 
1, TAB-2, TAB-3, IKK-α, IKK-β, IKK-γ and β-TrCP as well as SPSB1 or an Rluc only construct. Rluc 186 
activity was measured before and after immunoprecipitation of FLAG-SPSB1 and RLuc ratios were 187 
calculated. Using this assay none of the tested NF-κB components interacted with SPSB1 (Fig. S2). The 188 
second approach relied on reporter assays in which NF-κB was triggered by over-expression of signalling 189 
molecules. SPSB1 was able to suppress NF-κB activation deriving from the adaptors TRAF-6 (Fig. 3B) 190 
and TRAF-2 (Fig. 3C); the RNA sensor RIG-I (Fig. 3D), which activates NF-κB at the level of TRAF-6; 191 
the kinase IKK-β (Fig. 3E); and the DNA sensors cGAS and STING (Fig. 3F), which converge on the NF-192 
κB pathway at the level of the IKK complex. Taken together, these data indicated that SPSB1 acted 193 
downstream of these molecules. In agreement with this observation SPSB1 inhibited NF-κB activation 194 
triggered by p65 over-expression (Fig. 3G).  195 
 196 
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We also created a panel of SPSB1 mutants (Fig. 4A) including one lacking the entire C-terminal SOCS-197 
box domain (ΔSOCS), one lacking the first 85 amino acids (Δ85) and one containing the point mutation 198 
R77A. These two have been described to disrupt the interaction between SPSB1 and its targets 199 
(Filippakopoulos et al., 2010;D'Cruz et al., 2013). All these constructs expressed at similar levels (Fig. 4B) 200 
and suppressed p65-induced NF-κB activation to similar extent with the exception of SPSB1-ΔSOCS, 201 
which was clearly impaired (Fig. 4C). This indicated that the SOCS-box domain is needed for SPSB1 to 202 
show inhibitory activity. 203 
 204 
SPSB1 does not interfere with IκBα phosphorylation or degradation 205 
 206 
If SPSB1 blocked p65-induced NF-κB activation, IκBα should be phosphorylated and degraded in the 207 
presence of SPSB1. To verify this, we first generated A549 stable cell lines expressing SPSB1 or GFP as a 208 
control protein using lentiviruses. Immunoblotting against FLAG revealed the successful transduction and 209 
expression of SPSB1 (Fig. 5A). To validate that SPSB1 expression was sufficient and functional in these 210 
cells, the expression of ICAM-1 (Fig. 5B) and iNOS (Fig. 5C), all of which contain NF-κB sites in their 211 
promoters, was assessed by quantitative PCR in response to IL-1β stimulation. The expression of all these 212 
genes was enhanced upon IL-1β treatment, but to a lower extent in cells expressing SPSB1.  213 
 214 
We then assessed the kinetics of phosphorylation and degradation of IκBα in these cells. Exposure to IL-215 
1β induced significant p-IκBα levels in as little as 5 mins and this was concomitant with subsequent 216 
degradation of IκBα (Fig. 6). The presence of SPSB1 had no effect on either the intensity or the kinetics of 217 
phosphorylation of IκBα, nor its subsequent degradation, and this was confirmed by densitometric analysis 218 
of the images (Fig. S3). We also assessed the phosphorylation of Ser536 in p65, a cytoplasmic event that 219 
relates to p65 activation (Christian et al., 2016). No differences in p-p65 levels were observed between 220 
SPSB1 and its control cell line (Fig. 6), and this was also confirmed by densitometry (Fig. S3). In addition, 221 
the total levels of p65 remained similar in the presence of SPSB1, suggesting that this protein does not 222 
affect p65 turnover. 223 
 224 
SPSB1 does not interfere with p65 translocation 225 
 226 
When IκBα is phosphorylated and degraded, the NF-κB heterodimer is free to translocate into the nucleus 227 
and induce the expression of NF-κB-dependent genes. We therefore assessed whether p65 would 228 
translocate in the presence of SPSB1. Cells were challenged with IL-1β and after 30 mins stained for p65 229 
and SPSB1 (FLAG). In control unstimulated cells p65 located in the cytosol and moved to the nucleus upon 230 
stimulation (Fig. 7). In SPSB1-expressing cells, p65 translocated to the nucleus to the same extent upon IL-231 
1β exposure and no differences were observed. This indicated that SPSB1 was not able to restrict p65 232 
translocation. Interestingly, SPSB1 showed both nuclear and cytosolic distribution in unstimulated cells, 233 
but a notable nuclear localisation after stimulation, indicating that either SPSB1, or its target, alters its 234 
cellular distribution in response to NF-κB signalling.  235 
 236 
SPSB1 associates with p65 237 
 238 
The fact that SPSB1 shadows p65 nuclear translocation (Fig. 7) and inhibits p65-induced NF-κB activation 239 
(Fig. 3G) suggested an association between SPSB1 and p65. We thus immunoprecipitated HA-tagged p65 240 
in the presence of SPSB1 or GFP as a control and observed a specific co-precipitation between SPSB1 and 241 
p65 (Fig. 8A). To confirm this interaction at naturals levels, we immunoprecipitated endogenous p65 from 242 
A549 cells treated with IL-1β for 30 min or left untreated. Despite some unspecific binding in the isotype 243 
control samples we observed a significant enrichment for SPSB1 in the p65 pull-down from cells previously 244 
treated with IL-1β (Fig. 8B), indicating that activation of the pathway enhances the interaction between 245 
SPSB1 and p65. This is in agreement with the prominent nuclear localisation of SPSB1 after IL-1β 246 
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treatment (Fig. 7) and its capacity to inhibit NF-κB activation after ectopic expression of p65 (Fig. 3G). 247 
Given the inability of SPSB1-ΔSOCS to suppress NF-κB activation, we also assessed the potential 248 
interaction between this mutant and p65. Full-length SPSB1, SPSB1-ΔSOCS and cGAS as a control were 249 
expressed in HEK293T cells and subjected to affinity purification and immunoblotting (Fig. 8C). Whilst 250 
no binding was observed for cGAS, both full-length and ΔSOCS interacted efficiently with p65, indicating 251 
that the SOCS-box domain is dispensable for binding to p65. Given that the SOCS-box domain is known 252 
to mediate interaction with Cul-5, these data suggest that although SPSB1-ΔSOCS interacts with p65, this 253 
is not sufficient to inhibit p65 transcriptional activity and that this requires engagement with CRL5 254 
complexes, presumably to allow ubiquitylation. Collectively, these data revealed that SPSB1 is a potent 255 
suppressor of NF-κB responses that interacts with p65 after p65 activation in a manner that does not affect 256 
stability or translocation. 257 
 258 
SPSB1 inhibits NF-κB activation induced by RSV infection 259 
 260 
Viruses are common inducers of NF-κB signalling. Respiratory syncytial virus (RSV) is a common 261 
respiratory pathogen and the main cause of airway inflammation in infants, and it is known to trigger NF-262 
κB and type I IFN responses in the airway (Sun and Lopez, 2017). To address the role of SPSB1 in 263 
controlling virus-induced responses, we infected our A549 cell lines with 2 PFU/cell of RSV and performed 264 
qPCR analysis on a number of cytokines. RSV infection triggered measurable levels of IFN-β in these cells 265 
and this was reduced by SPSB1 (Fig. 9A). Interestingly, we also observed a significant reduction in the 266 
levels of IFN-dependent genes such as ISG54 and OAS1 (Fig. 9B and 9C). Given the inability of SPSB1 to 267 
directly downregulate the JAK-STAT signalling pathway, these results indicate that SPSB1 effective 268 
suppression of IFN-β production impacted on the expression of these antiviral genes.  269 
 270 
Discussion 271 
 272 
Here we have explored the role of CRL5 complexes in NF-κB activation in airway epithelial cells using an 273 
unbiased screen for SOCS-box proteins. This screen has identified SPSB1 as a novel regulator of the 274 
pathway: SPSB1 depletion resulted in enhanced NF-κB-dependent transcriptional activity (Fig. 1) and this 275 
effect was reversed by SPSB1 overexpression (Fig. 2 and Fig. 3). In addition, our results indicate that 276 
SPSB1 controls NF-κB activation when cells were exposed to inflammatory cytokines (Fig. 5) as well as 277 
viruses (Fig. 9). Therefore, our work highlights SPSB1 as a novel and important participant in the signalling 278 
network that governs the production of NF-κB-dependent cytokines. 279 
 280 
SPSB1 is the first member of the SPSB family, a group of 4 proteins (SPSB1-4) characterised by the 281 
presence of a SPRY domain and a C-terminal SOCS box domain that engages with the CRL E3 ubiquitin 282 
ligase complex (Linossi and Nicholson, 2012). SPSB1, SPSB2 and SPSB4 are known to target the inducible 283 
nitric oxide synthase (iNOS) via the SPRY domain and trigger its proteasomal degradation (Kuang et al., 284 
2010;Lewis et al., 2011;Nishiya et al., 2011). In addition, SPSB1 regulates multiple cancer-associated 285 
pathways via interactions with c-met (Wang et al., 2005;Feng et al., 2014), the apoptosis-related protein 286 
Par-4 (Masters et al., 2006;Filippakopoulos et al., 2010) and the TGF-β receptor (Liu et al., 2015;Liu et al., 287 
2018). The specific motif that SPSB1 recognises on its targets was suggested to be (D/E)-(I/L)-N-N-N. 288 
However, the degron recognised by SPSB1 in the TGF-β receptor has been mapped to N-I-N-H-N-T (Liu 289 
et al., 2015). The difference in sequence of the proposed motifs suggests the existence of more SPSB1 290 
degrons than previously inventoried. Interestingly, SPSB1 has recently been shown to direct non-291 
degradative ubiquitylation in the nucleus to regulate alternative splicing (Wang et al., 2017). Our results 292 
reveal that SPSB1 restricts the extent of NF-κB activation induced by cytokines and viruses downstream of 293 
IκBα degradation and p65 translocation and associates with p65. This indicates that SPSB1 targets p65 in 294 
the nucleus or in the cytosol in a manner that does not affect its ability to translocate. SPSB1 targeting 295 
affects the transactivation potential of p65, but not its stability. An interesting possibility is that SPSB1 296 
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mediates non-degradative ubiquitylation of p65 itself and affects its transcriptional activity perhaps by 297 
competing with other PTM known to activate p65 such as acetylation (Perkins, 2006). Our results showing 298 
that an SPSB1 mutant that lacks the CRL5-interacting SOCS-box domain lost inhibitory capacity would 299 
support this notion, and the ability of SPSB1 to catalyse non-degradative K29 ubiquitin chains has already 300 
been described (Wang et al., 2017). Interestingly, this mutant retained the ability to interact with p65, 301 
indicating that binding to p65 is not sufficient to suppress NF-κB activation and optimal inhibition requires 302 
engagement with Cul-5, which complexes with the E2 enzyme required for ubiquitylation. Thus, SPSB1 303 
would limit signal-induced p65 activation without triggering ubiquitin-dependent proteolysis.  304 
 305 
An SPSB1 substrate that is of particular importance in innate immunity and inflammation is iNOS (also 306 
known as NOS2) and its catalytic product NO. iNOS is an inducible gene that is expressed at low levels in 307 
human respiratory epithelia and is upregulated in disease. Activation of NF-κB and STAT1 in response to 308 
TLR agonists and cytokines is largely responsible for the transcriptional induction of iNOS expression 309 
(Pautz et al., 2010). Interestingly, SPSB1 expression is also enhanced by NF-κB and type I IFN (Lewis et 310 
al., 2011). This indicates that SPSB1 expression is tightly regulated and that, according to the data presented 311 
here, represents a negative feed-back loop on NF-κB. This also implies that SPSB1 has a dual role 312 
controlling iNOS: i) it limits iNOS expression by downregulating NF-κB activation, and ii) it drives iNOS 313 
ubiquitylation and its proteasome-dependent destruction. SPSB1 is thus a unique molecule controlling 314 
inflammatory responses. We did not observe a role for other iNOS-modulating CLR5 complexes such as 315 
SPSB2 or SPSB4 in inhibiting NF-κB activation, although we cannot rule out that the RNAi depletion for 316 
SPSB2 and SPSB4 in our screen was not sufficiently efficient. It would therefore be interesting to assess 317 
the role of these molecules as well as its paralogue FBXO45 in the regulation of NF-κB signalling.  318 
 319 
Our screen has also highlighted other molecules that might regulate NF-κB signalling. For instance, 320 
depletion of SOCS5 led to a substantial reduction in NF-κB activation. SOCS5 has been shown to regulate 321 
IL-4 (Seki et al., 2002) and epidermal growth factor receptor EGFR) signalling (Kario et al., 322 
2005;Nicholson et al., 2005). In addition, inhibition of EGFR/PI3K signalling by SOCS5 conferred 323 
protection against influenza infection (Kedzierski et al., 2017). Our data suggest that SOCS5 is a critical 324 
factor required for NF-κB activation since its depletion severely impaired NF-κB reporter activation (26 % 325 
upon stimulation). This may indicate that SOCS5 is necessary to activate NF-κB during viral infection and 326 
mount a protective response. We also noticed that depletion of SOCS1, a known inhibitor of NF-κB and 327 
JAK/STAT signalling (Kamizono et al., 2001;Strebovsky et al., 2011), did not result in significant changes 328 
in NF-κB activation in our screen. Further analysis of gene expression data revealed that SOCS1 is not 329 
expressed in A549 cells (Barretina et al., 2012), which accounts for these results.  330 
 331 
Excessive inflammation is central to a large number of pathologies. For instance, in the respiratory tract 332 
obstructive lung diseases such as asthma or chronic obstructive pulmonary disease (COPD) are 333 
characterised by inflammatory gene expression and the production of inflammatory mediators that enhance 334 
the recruitment of inflammatory cells (Schuliga, 2015). NF-κB is an important player in this multifactorial 335 
diseases as evidenced by the fact that the therapeutic efficacy of the main treatment for asthma - 336 
glucocorticoids – is thought to be largely caused by their ability to suppress NF-κB and AP-1 responses 337 
(Hayashi et al., 2004). In these diseases, NF-κB occurs largely in response to cytokines such as IL-1β and 338 
TNF-α or by infection with viruses during exacerbations (Edwards et al., 2009). Mechanisms that limit this 339 
excessive inflammation are crucial to maintain homeostasis. E3 ubiquitin ligases are potent post-340 
translational regulators with capacity to regulate inflammatory responses as recently reported for the E3 341 
ligase TRIM29 and its critical role in regulating NEMO stability in alveolar macrophages and consequently 342 
the levels of IRF-3 and NF-κB activation (Xing et al., 2016). Here we present the novel finding that a 343 
member of the CRL5 family, SPSB1, downregulates the expression of inflammatory cytokines and other 344 
NF-κB-dependent genes in airway epithelial cells exposed to cytokines and viral infection. SPSB1 may 345 
thus have regulatory functions in chronic inflammatory disorders of the respiratory tract as well as acute 346 
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virus-induced exacerbations. Our work reveals a new connection between CRL and innate immunity and 347 
may offer alternative strategies for the manipulation of NF-κB transcriptional activity in inflammatory 348 
pathologies.  349 
 350 
Material and Methods 351 
 352 
Cells, viruses and agonists 353 
 354 
A549 and HEK293T cells were grown in Dulbecco Modified Eagle medium (DMEM, Life Technologies) 355 
supplemented with 10 % heat-inactivated fetal calf serum (FCS, Biowest), 100 U/mL penicillin and 100 356 
μg/mL Streptomycin (Pen/Strep, Invitrogen). The A549-κB-LUC cells were previously described (Sumner 357 
et al., 2014). A549-SPSB1 and A549-GFP stable cell lines were grown as above with the addition of 2 358 
μg/mL puromycin (Invitrogen). SeV strain Cantell was from Greg Towers (University College London, 359 
United Kingdom) and RSV strain A2 was from Gill Elliott (University of Surrey, United Kingdom). IL-1β, 360 
TNF-α and IFN-β were from Peprotech. PMA was from Santa Cruz. 361 
 362 
RNAi depletion screens 363 
 364 
siRNA sequences targeting CRL5 adaptors were purchased from Horizon Discovery and resuspended in 365 
nuclease-free water to 1 μM final concentration. A549-κB-LUC cells were reverse-transfected in triplicate 366 
replicates with 30 nM siRNA using Interferin-HTS (Polyplus) and incubated for 72 h. The cells were then 367 
stimulated with 1 ng/mL of IL-1β for 6 h and subsequently washed with ice-cold PBS and lysed in Passive 368 
Lysis Buffer (PLB; Promega). Luciferase activity was measured in a Clariostar plate reader (BMG Biotech) 369 
and data for each sample were normalised to its non-stimulated condition and plotted as mean % ± SD over 370 
the NTC-transfected control. Data shown are representative of 2 independent screens showing similar 371 
results. Cells were also reverse-transfected in identical manner to determine cell viability 72 h post-372 
transfection using CellTiter-Glo (Promega) following manufacturer’s recommendations.  373 
 374 
shRNA depletion and overexpression of SPSB1 in A549 cells 375 
 376 
A549 cells were depleted for SPSB1 using specific short hairpin sequences expressed from the HIV-1-377 
based shRNA expression vector HIVSiren (Schaller et al., 2011). These shRNA sequences were generated 378 
using an open-access algorithm (RNAi designer, ThermoFisher) and were as follows: Top shRNA strand: 379 
5’- GATCCACACAACCCTCGTGGGGAACGAATTCCCCACGAGGGTTGTG-3’; bottom SPSB1 380 
strand: 5’- AATTCACAACCCTCGTGGGGAATTCGTTCCCCACGAGGGTTGTGTG-3’. Lentiviral 381 
particles were produced by transfection of HEK293T cells (seeded in 100 mm dishes) with 9 µg of 382 
pHIVSIREN shRNA, 5 µg of p8.91 packaging plasmid (Zufferey et al., 1997), and 3 µg of vesicular 383 
stomatitis virus-G glycoprotein expressing plasmid pMDG (Genscript) using polyethylenimine (PEI; 384 
Polysciences). Virus supernatants were harvested at 48 and 72 h post-transfection, pooled, and used to 385 
transduce A549 cells, which were subsequently selected for puromycin resistance (Invivogen, 2 µg/ml).  386 
 387 
To generate A549 cells overexpressing SPSB1, SPSB1 was PCR amplified using primers 5’-GAA GCG 388 
GCC GCG GGT CAG AAG GTC ACT GAG-3’ (fwd) and 5’-GAC TCT AGA TCA CTG GTA GAG 389 
GAG GTA GG-3’ (rev). The PCR product was subsequently ligated into a pcDNA4/TO expression vector 390 
(Invitrogen) previously modified to express genes in frame with 3 N-terminal copies of the FLAG epitope, 391 
an N-terminal copy of the V5 epitope, or an N-terminal tandem affinity purification tag containing 2 copies 392 
of the strep tag and 1 copy of the FLAG tag as previously described (Maluquer de Motes et al., 2014;Odon 393 
et al., 2018). FLAG-SPSB1 was then subcloned into a lentivirus vector carrying puromycin resistance (a 394 
gift from Greg Towers). Lentiviral particles were produced in HEK293T as above and virus supernatants 395 
were harvested at 48 and 72 h post-transfection. FLAG-SPSB1 was also used as a template to generate 396 
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deletion mutants ΔSOCS (encompassing amino acids 1-231) and Δ85 (encompassing amino acids 86-273) 397 
using primers amplifying the specified regions. Mutant R77A was generated by site-directed mutagenesis 398 
using KOD hot-start DNA polymerase (Millipore).  399 
 400 
Quantitative PCR 401 
 402 
RNA from confluent 6-well plates of A549 cells was purified using the Total RNA Purification Kit (Norgen 403 
Biotech). One µg of RNA was transformed into cDNA using Superscript III reverse transcriptase 404 
(Invitrogen). cDNA was diluted 1:5 in water and used as a template for real-time PCR using SYBR® Green 405 
PCR master mix (Applied Biosystems) in a LightCycler® 96 (Roche). Expression of each gene was 406 
normalized to an internal control (18S) and these values were then normalized to the shCtl or GFP control 407 
cells to yield a fold induction. Primers used for the detection of CXCL10 (Gao et al., 2013), IFNβ and 18S 408 
(Georgana et al., 2018) have been described. Primers used for iNOS detection were 5’-409 
ACAAGCCTACCCCTCCAGAT (fwd) and 5’-TCCCGTCAGTTGGTAGGTTC (rev). Data shown are 410 
representative of at least 3 independent experiments showing similar results, each performed in triplicate 411 
and plotted as mean ± SD. 412 
 413 
Reporter gene assays 414 
 415 
HEK293T cells were seeded in 96-well plates and transfected with the indicated reporters and expression 416 
vectors using PEI as described in the figure legends. The reporter plasmids have been described previously 417 
(Mansur et al., 2013). After 24 h the cells were stimulated by exposure to different agonists or by co-418 
transfection with activating plasmids as indicated in the figure legends. Plasmids for signalling molecules 419 
have been described (Odon et al., 2018) with the exception of untagged and HA-tagged p65 that were from 420 
Geoffrey Smith (University of Cambridge, United Kingdom). TAP-tagged VACV C6 (Unterholzner et al., 421 
2011) and HA-tagged VACV A49 (Mansur et al., 2013) have been described. After stimulation cells were 422 
washed with ice-cold PBS and lysed with PLB. Luciferase activity was measured in a Clariostar plate reader 423 
and firefly and renilla ratios were calculated for each condition. Data were normalised to mock-infected 424 
samples or samples transfected with an empty vector and presented as a fold increase. In all cases data 425 
shown are representative of at least 3 independent experiments showing similar results, each performed in 426 
triplicate and plotted as mean ± SD. 427 
 428 
LUMIER assays 429 
 430 
HEK293T cells were co-transfected with FLAG-SPSB1 and Rluc fusions for NF-κB signalling components 431 
for 24 h. Rluc fusions were from Felix Randow (Laboratory of Molecular Biology, University of 432 
Cambridge, United Kingdom) and/or have been previously described (Chen et al., 2008;Thurston et al., 433 
2009;Maluquer de Motes et al., 2011;Maluquer de Motes and Smith, 2017). Cells were lysed in IP buffer 434 
(20mM Tris-HCl pH7.4, 150mM NaCl, 10mM CaCl2, 0.1 % Triton-X and 10 % glycerol) supplemented 435 
with protease inhibitors (Roche) and cleared lysates were subjected to affinity purification (AP) with 436 
streptavidin beads for 6 h at 4 °C. The beads were then washed 3 times with lysis buffer prior to elution 437 
with biotin (10 mg/ml) diluted in PLB. Luciferase activity was measured and data were plotted as a binding 438 
fold over Rluc-only control.  439 
 440 
Pull-down assays 441 
 442 
HEK293T cells were seeded in 10-cm dishes and transfected with 5 μg of the indicated plasmids using PEI. 443 
After 24 h cells were lysed with IP buffer as above. Cleared lysates were incubated with HA antibody 444 
(Sigma) for 16 h at 4 °C and subsequently Protein G beads (Santa Cruz) were added for a further 2 h. For 445 
IP at endogenous levels cleared lysates from 15-cm dishes of A549 cells were incubated with p65 antibody 446 
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or an isotype control and Protein G beads as above. For streptavidin affinity purification assays HEK293T 447 
cells in 10-cm dishes were transfected with 5 μg of the indicated plasmids using PEI. After 24 h cells were 448 
lysed with IP buffer as above. Cleared lysates were incubated with Streptavidin beads (Sigma) for 16 h at 449 
4 °C. The beads were then washed 3 times with IP buffer prior to incubation at 95 °C for 5 min in Laemmli 450 
loading buffer to elute bound proteins. Cleared lysates and pull-down fractions were analysed by SDS-451 
PAGE and immunoblotting. Data shown are representative of at least 3 independent experiments showing 452 
similar results. 453 
 454 
SDS-PAGE and immunoblotting 455 
 456 
Cells were lysed in IP or RIPA buffer (50mM Tris-HCl pH8, 150mM NaCl, 1 % NP-40, 0.5 % sodium 457 
deoxycholate and 0.1 % SDS) and resolved by SDS-PAGE and transferred to nitrocellulose membranes 458 
(GE Healthcare) using a Trans-Blot semi-dry transfer unit (Bio-Rad). Membranes were blocked in 0.1 % 459 
Tween PBS supplemented with 5% skimmed milk (Sigma) and subjected to immunoblotting with the 460 
following primary antibodies at the indicated dilutions: SPSB1 (Abcam, 1:1,000); FLAG (Sigma, 1:1,000); 461 
IκBα (Cell Signalling, 1:1,000); p-IκBα (S32/36) (5A5) (Cell Signalling, 1:1,000); p65 (Santa Cruz, 1:500); 462 
p-p65 (Ser536) (Santa Cruz, 1:500); V5 (BioRad, 1:5,000); α-Tubulin (Upstate Biotech, 1:10,000); HA 463 
(Sigma, 1:2,000). Primary antibodies were detected using IRDye-conjugated secondary antibodies in an 464 
Odyssey Infrared Imager (LI-COR Biosciences). Densitometric analyses were performed using Image-J. 465 
 466 
Immunofluorescence 467 
 468 
Cells were seeded into 6-well plates containing sterile glass coverslips. Following stimulation with IL-1β 469 
(25 ng/ml) for 30 min, the cells were washed twice with ice-cold PBS and fixed in 4 % (w/v) 470 
paraformaldehyde. The cells were then quenched in 150 mM ammonium chloride, permeabilized in 0.1 % 471 
(v/v) Triton X-100 in PBS, and blocked for 30 min in 5 % (v/v) FBS in PBS. The cells were stained with 472 
rabbit anti-FLAG (Sigma, 1:300) and mouse anti-p65 antibody (Santa Cruz, 1:50) for 1 h, followed by 473 
incubation with goat anti-rabbit IgG Alexa Fluor 488 and goat anti-mouse IgG Alexa Fluor 568 secondary 474 
antibodies (Invitrogen). Coverslips were mounted in Mowiol 4-88 (Calbiochem) containing DAPI (4′,6-475 
diamidino-2-phenylindole). Images were taken on a LSM 510 META confocal laser scanning microscope 476 
(Zeiss) using the LSM image browser software (Zeiss).  477 
 478 
Statistical analysis 479 
 480 
Statistical significance was determined using an unpaired Student’s t-test with Welch’s correction where 481 
appropriate. 482 
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FIGURES 679 
 680 
 681 
 682 
 683 
Figure 1. SPSB1 is a novel negative regulator of the NF-κB pathway. (A) IL-1β-mediated NF-κB 684 
activation (red bars, left axis) and cell viability (black circles, right axis) observed for A549-κB-Luc cells 685 
transfected with 30 nM siRNA targeting human CRL-5 adaptor proteins. Data were normalised to the non-686 
stimulated condition and plotted as a % over NTC data. (B) The individual siRNA targeting SPSB1 from 687 
(A) were tested individually and NF-κB activation was calculated as a % over NTC data. (C) A549 cells 688 
were transduced with a lentiviral construct containing shRNA against SPSB1 (shSPSB1) or NTC (shCtl). 689 
Cells were lysed in RIPA buffer and subjected to immunoblotting against endogenous SPSB1 and α-tubulin. 690 
(D-E) shSPSB1 and shCtl cells were treated with IL-1β (25 ng/ml) for 6 h, and the mRNA levels of (D) 691 
iNOS and (E) IL-6 were measured by qPCR. Means and standard deviations over the non-stimulated 692 
conditions are shown. Statistical significance was determined using an unpaired Student’s t-test (*p ≤ 0.05). 693 
In all panels, data are representative of at least 2 experiments performed independently and showing similar 694 
results.  695 
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Figure 2. SPSB1 blocks NF-κB activation in response to IL-1β and TNF-α agonists, but it does not 699 
affect IRF-3, AP-1 or the JAK-STAT signalling pathway. (A-B) HEK293T cells were transfected with 700 
increasing doses of SPSB1-FLAG as indicated together with 70 ng/well of pNF-κB-LUC and 10 ng/well 701 
of pTK-Renilla reporters. After 24 h the cells were stimulated with (A) 20 ng/mL of IL-1β or (B) 50 ng/mL 702 
of TNF-α for 6 h. (C-E) HEK293T cells were transfected with (C) 70 ng/mL of pIFNβ-LUC, (D) 200 703 
ng/well of pAP1-LUC, or (D) 70 ng/well of pISRE-LUC as well as 10 ng/well pTK-Renilla reporters, 704 
together with 25 ng of SPSB1-FLAG, the indicated positive control plasmids, or the corresponding empty 705 
vector (EV). After 24 h the cells were stimulated with (C) SeV for a further 24 h, (D) 10 ng/ml of PMA for 706 
a further 24 h, or (E) 50 ng/mL of IFN-β for a further 8 h. Data are representative of at least 3 independent 707 
experiments, each performed in triplicate. Means and standard deviations are shown and statistical 708 
significance was determined using an unpaired Student’s t-test (*p ≤ 0.05, **p≤ 0.01, ***p ≤ 0.001). 709 
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Figure 3. SPSB1 blocks NF-κB signalling downstream, or at the level, of the p50/p65 complex. (A) 713 
Schematic representation of the NF-κB key molecules and the cross-link with the cGAS/STING pathway. 714 
(B-G) HEK293T cells were transfected with 70 ng/well of pNF-κB-LUC and 10 ng/well of pTK-Renilla, 715 
and two doses of SPSB1-FLAG (25 and 50 ng) or an empty vector (EV). The cells were stimulated by co-716 
transfection of (B) TRAF-6, (C) TRAF-2, (D) RIG-I-CARD, (E) IKK-β, (F) cGAS and STING, or (G) p65. 717 
VACV protein A49 was used as a control. Data are representative of at least 3 independent experiments, 718 
each performed in triplicate. Means and standard deviations are shown and statistical significance was 719 
determined using an unpaired Student’s t-test (*p ≤ 0.05, ***p ≤ 0.001).  720 
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Figure 4: SPSB1 SOCS-box domain is needed for NF-κB inhibition. (A) Schematic representation of 724 
SPBS1 mutants. (B) HEK293T cells were transfected with the indicated constructs and harvested in RIPA 725 
buffer 24 h after transfection. Lysates were subjected to immunoblotting against FLAG and α-tubulin. (C) 726 
HEK293T cells were transfected with 70 ng/well of pNF-κB-LUC and 10 ng/well of pTK-Renilla, and 25 727 
ng/well of each SPSB1 construct. The cells were stimulated by co-transfection of p65. Data are 728 
representative of at least 3 independent experiments, each performed in triplicate. Means and standard 729 
deviations are shown and statistical significance was determined using an unpaired Student’s t-test (**p ≤ 730 
0.01). 731 
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Figure 5. Expression levels of NF-κB-dependent genes in A549 cells stably expressing SPSB1 upon 735 
induction with IL-1β. (A) A549 cells were transduced with lentiviral constructs expressing FLAG-GFP or 736 
SPSB1. Cells were harvested in RIPA buffer and subjected to immunoblotting against FLAG and α-tubulin. 737 
(B-D) A549 cells stably expressing GFP or SPSB1 were treated with 25 ng/ml of IL-1β for 6 h. The mRNA 738 
levels of (B) ICAM-1 and (C) iNOS were measured by qPCR. Data are presented as fold increase over the 739 
non-stimulated condition and representative of at least 2 independent experiments, each performed in 740 
triplicate. Means and standard deviations are shown and statistical significance was determined using an 741 
unpaired Student’s t-test (*p ≤ 0.05). 742 
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Figure 6. IκBα degradation in the presence of SPSB1. A549 cells stably expressing FLAG-GFP or 747 
FLAG-SPSB1 were treated with 25 ng/ml of IL-1β for the indicated length of time. Cells were harvested 748 
in RIPA buffer supplemented with protease and phosphatase inhibitors and lysates were subjected to 749 
immunoblotting against the indicated proteins or the FLAG epitope. Data are representative of 3 750 
experiments performed independently.  751 
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Figure 7. SPSB1 does not interfere with p65 translocation. A549 cells stably expressing FLAG-SPSB1 756 
or their parental control were treated with 25 ng/mL of IL-1β for 30 mins or left unstimulated (NS). The 757 
cells were then fixed and stained for FLAG (green) and p65 (red) together with DAPI (blue) to visualise 758 
cell nuclei. Merged images are also shown. Images are representative of multiple visual fields showing the 759 
same results. Bar, 10 μm.  760 
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Figure 8. SPSB1 associates with p65. (A) HEK293T cells transfected with HA-p65 and FLAG-SPSB1 or 765 
GFP were lysed and subjected to HA immunoprecipitation (IP). Lysates and final IP eluates were 766 
immunoblotted (IB) against the indicated tags. IgG heavy chain is indicated with an arrow. (B) A549 cells 767 
were treated with 25 ng/mL of IL-1β for 30 mins or left untreated and lysed in IP buffer before incubation 768 
with anti-p65 antibody or an isotype control. Both lysates and IP fractions were subjected to 769 
immunoblotting against the indicated proteins. SPSB1 and IgG light chain are indicated with arrows. (C) 770 
HEK293T cells transfected with HA-p65 and TAP-tagged full-length SPSB1, ΔSOCS-box or cGAS as a 771 
control were lysed and subjected to Streptavidin affinity purification (AP). Lysates and final AP eluates 772 
were immunoblotted against the indicated tags or α-tubulin. 773 
  774 
 SPSB1 inhibition of NF-κB signalling 
23 
 775 
 776 
Figure 9. SPSB1 limits the innate immune response to RSV infection. A549 cells stably expressing GFP 777 
or SPSB1 were infected with 2 PFU/cell of RSV for 24 h. The mRNA levels of (A) IFN-β, (B) ISG54 and 778 
(C) OAS1 were measured by qPCR. Data are representative of at least 3 independent experiments, each 779 
performed in triplicate. Means and standard deviations are shown and statistical significance was 780 
determined using an unpaired Student’s t-test (*p ≤ 0.05). 781 
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Figure S1. SPSB1 self-associates. (A) HEK293T cells were co-transfected with V5-tagged SPSB1, or an 785 
empty vector (EV) and FLAG-tagged SPSB1. The cells were lysed in IP buffer and subjected to FLAG IP. 786 
The IP and cell lysates were loaded onto an SDS-PAGE gel and immunoblotted against V5, FLAG and α-787 
tubulin. (B) HEK293T cells were co-transfected in triplicates with RLuc-tagged SPSB1, or RLuc-only (EV) 788 
as a control and SPSB1-nTAP. Cells were lysed in IP buffer supplemented with protease inhibitors and 789 
lysates subjected to AP using streptavidin beads. The beads were eluted with biotin and the luciferase 790 
activity was measured both in lysates and eluates. The binding fold was calculated as an eluate/lysate ratio 791 
and this was normalised to the EV control. The experiments have been repeated three times independently. 792 
Means and standard deviations are shown and statistical significance was determined by using an unpaired 793 
Student’s t-test (***p ≤ 0.001). 794 
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Figure S2. SPSB1 does not associate with any of the NF-κB components tested in LUMIER screens. 798 
HEK293T cells were co-transfected with SPSB1-nTAP and different components of the NF-κB pathway 799 
fused to RLuc, or an Rluc-only (EV) control. SPSB1 self-association was used a positive control. Cells 800 
were treated as in Fig. S1 and the binding fold was calculated as an eluate/lysate ratio and this was 801 
normalised to the EV control. Data are representative of 2 experiments showing similar results. 802 
  803 
 SPSB1 inhibition of NF-κB signalling 
26 
 804 
 805 
 806 
Figure S3. Densitometric analysis of the phosphorylation and degradation of IκBα and p65 in GFP- 807 
or SPSB1-expressing A549 cells. Immunoblotting results from Fig. 6 were quantitated (arbitrary units) 808 
and plotted over time.  809 
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Table S1. RNAi sequences employed for the specific knock-down of CRL5 substrate adaptor 811 
molecules. 812 
Gene Symbol Accession number Duplex Number Sequence 
FBXW11 NM_033645 D-003490-02 GCACAUUGGUGGAACAUUC 
FBXW11 NM_033645 D-003490-03 GUUAGUGGAUCAUCAGAUA 
FBXW11 NM_033645 D-003490-04 GAGCAAGGCUUAGAUCACA 
FBXW11 NM_033645 D-003490-17 AGAAGUAAAUCGACCGUCA 
ASB1 NM_001040445 D-017197-01 GAAGAAAAGUGGACCCUGA 
ASB1 NM_001040445 D-017197-02 GAGCCAACCUGAAUCUAGU 
ASB1 NM_001040445 D-017197-03 GCAAACACCGGCUUCAUCU 
ASB1 NM_001040445 D-017197-04 GCGCGAACCCUGACUUCAA 
ASB2 NM_016150 D-009575-01 GAAAGGCCAUUGGGAAAUA 
ASB2 NM_016150 D-009575-02 GCACGAGGCCGCAUACUAU 
ASB2 NM_016150 D-009575-03 GAACAUCGACGCCUAUAUC 
ASB2 NM_016150 D-009575-04 UUAGAUACCUGAAAUACGA 
ASB3 NM_016115 D-017457-01 GGACAAAGCUACACCCUUG 
ASB3 NM_016115 D-017457-02 GAAAGCUUGAGCAUACUUA 
ASB3 NM_016115 D-017457-03 GAACGUCUACGGUCUGACA 
ASB3 NM_016115 D-017457-04 CUUUGGAGUUUACUAAUUG 
ASB4 NM_016116 D-013339-01 CUACAAAGCCGAAGUCAAU 
ASB4 NM_016116 D-013339-02 CCAAGUUAGUUAAGAGAAA 
ASB4 NM_016116 D-013339-03 CAAGGUUACUGGUUGCCUA 
ASB4 NM_016116 D-013339-04 CCACAAUGCUACAAUCAAC 
ASB5 NM_080874 D-017458-02 GGAUAUUGCUUCAACAUGA 
ASB5 NM_080874 D-017458-03 GCCGUUUGCUCAACAAUUA 
ASB5 NM_080874 D-017458-04 CAAGGAAGCGGCAAGGAUA 
ASB5 NM_080874 D-017458-17 UGUAAUGGAUAACGUGCAU 
ASB6 NM_017873 D-013355-01 GAACAUUCGUCUCUUACUG 
ASB6 NM_017873 D-013355-02 GGAGGAUCAUCUUCGAGUA 
ASB6 NM_017873 D-013355-03 GCAACGCCCUGCUCAAGAU 
ASB6 NM_017873 D-013355-04 CUGAAGAGCUUUAAACUGC 
ASB7 NM_024708 D-012930-01 GUGCACGGAUGUUAUAUAA 
ASB7 NM_024708 D-012930-02 GGAGCGACAUCAUUAAUGC 
ASB7 NM_024708 D-012930-03 GCGAUACGCCGUGAUCAAA 
ASB7 NM_024708 D-012930-04 CGAACACACGGAACUAUGA 
ASB8 NM_024095 D-014301-01 GGGCAGCCUUUAAGAACAA 
ASB8 NM_024095 D-014301-02 GCGCUUAAUCCGAACAAUU 
ASB8 NM_024095 D-014301-03 GCGCAGAGGUCAGAGUCAU 
ASB8 NM_024095 D-014301-04 CUGGAUGGGUAUAACCGAA 
ASB9 NM_024087 D-014295-01 GCAUCAGGCUUCUUUCAAA 
ASB9 NM_024087 D-014295-02 GCAUGGAGCUCAGGUGAAU 
ASB9 NM_024087 D-014295-03 GCACGGAGCCAGCGUUCAA 
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ASB9 NM_024087 D-014295-04 GAUGGGCGAUGCUGUGUCU 
ASB10 NM_080871 D-007725-01 CAACAUCGCUGACCAGGAU 
ASB10 NM_080871 D-007725-02 CAACAUCCGUGCUCUGAGA 
ASB10 NM_080871 D-007725-04 GAGUUGGUCUCCAGAAGAG 
ASB10 NM_080871 D-007725-17 GGUCUCUGACAUACGAAGA 
ASB11 NM_001012428 D-013267-01 GAGCUAACCUGAAGCGUAG 
ASB11 NM_001012428 D-013267-03 GCUCGGAACUCCCCUAUAU 
ASB11 NM_001012428 D-013267-04 CAGAGCCACUCGAACGAUU 
ASB11 NM_001012428 D-013267-18 CCGGAAGUGUCUCGGUCGA 
ASB12 NM_130388 D-013180-01 GAAAUCUGCCUCCAUCAUA 
ASB12 NM_130388 D-013180-02 GAAGCAGGCUCUCAAUCAA 
ASB12 NM_130388 D-013180-03 GAGUAUAUCCAGCUGUUAA 
ASB12 NM_130388 D-013180-04 CGUCAAAGCUAAACUACCA 
ASB13 NM_024701 D-012929-01 GGAAGAAGCCGUCUGACUA 
ASB13 NM_024701 D-012929-02 CCAAGUGCUUCGAGUACUA 
ASB13 NM_024701 D-012929-03 GAGAAGAUUGCCAAGUUAA 
ASB13 NM_024701 D-012929-04 CGAGAUGCUUAUCGAGUUU 
ASB14 NM_130387 D-013205-01 GUUGAAGGCUGGACAUCUA 
ASB14 NM_130387 D-013205-03 GAUACUAAGUUCUGUGAAG 
ASB14 NM_130387 D-013205-04 CUGCAGAGUUAACCCUUUA 
ASB14 NM_130387 D-013205-17 CCGCCUAAAGAUCCGGAAA 
ASB15 NM_080928 D-031158-01 CGACUCUGAUCAAACAUAA 
ASB15 NM_080928 D-031158-02 GAUAUUCAGCUAAGUAUUC 
ASB15 NM_080928 D-031158-04 GUCAAGCGAUGGUCAGCAA 
ASB15 NM_080928 D-031158-17 AGAGGAAGACUGCGCUGUA 
ASB16 NM_080863 D-013061-01 CCGAGCUGCUGCUGCGUUA 
ASB16 NM_080863 D-013061-02 AGACCCAGCUGUCCACCAA 
ASB16 NM_080863 D-013061-03 AGACUGUGCUCGACACCUG 
ASB16 NM_080863 D-013061-04 UCGCCGCACUGCUGGACUA 
ASB17 NM_080868 D-015284-01 GAACUUUCACACCAGUAUA 
ASB17 NM_080868 D-015284-02 GGAUAUCACUGUUACGAAC 
ASB17 NM_080868 D-015284-03 AAUGGUUGAUCGUGAAUUG 
ASB17 NM_080868 D-015284-04 UCACAGAUUACAUUGCAUU 
ASB18 NM_212556 D-032545-02 CAAUAAGGAUGAGAUGGAA 
ASB18 NM_212556 D-032545-03 GAAAUCUCCAGCCACGUUU 
ASB18 NM_212556 D-032545-04 GAAGACCUGUGCAUCUGUC 
ASB18 NM_212556 D-032545-17 CGGAUUACCUUCCCGACUA 
CISH NM_145071 D-017381-01 GACAACACCUGCAGAAGAU 
CISH NM_145071 D-017381-02 GAAGGCACGUUCUUAGUAC 
CISH NM_145071 D-017381-03 CCACUGCUGUACACCUAAA 
CISH NM_145071 D-017381-04 CCGACUACCUCCGACAGUA 
RAB40A NM_080879 D-008924-01 GCAAACCGCUGGUCUUUCG 
RAB40A NM_080879 D-008924-02 GGUAUGGAUCGAUGGAUUA 
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RAB40A NM_080879 D-008924-03 CGACCAGGCCUAUGACUUC 
RAB40A NM_080879 D-008924-05 GGGUAUGGAUCGAUGGAUU 
RAB40B NM_006822 D-008353-01 CGGCAUUGAUCGAUGGAUU 
RAB40B NM_006822 D-008353-02 CGGUGCACCUGGUGGACAA 
RAB40B NM_006822 D-008353-03 CGGCGGGCAUCGACUACAA 
RAB40B NM_006822 D-008353-04 GGUCUAUGACAUUGCGAAC 
RAB40C NM_021168 D-010368-01 GCAGUCCGGUGAAGAGCUA 
RAB40C NM_021168 D-010368-02 CAGAACUGCUCGCGGAGUA 
RAB40C NM_021168 D-010368-03 GUAACGGGAUCGACUACAA 
RAB40C NM_021168 D-010368-04 GCGCGUACGCAGAGAAGAA 
SOCS1 NM_003745 D-011511-07 GCAUCCGCGUGCACUUUCA 
SOCS1 NM_003745 D-011511-08 GGUGGCAGCCGACAAUGCA 
SOCS1 NM_003745 D-011511-09 GGACGCCUGCGGAUUCUAC 
SOCS1 NM_003745 D-011511-23 UGUUAUUACUUGCCUGGAA 
SOCS2 NM_003877 D-017604-01 GAAGGAACUUUCUUGAUUA 
SOCS2 NM_003877 D-017604-02 GAAGUAUGACUGUUAAUGA 
SOCS2 NM_003877 D-017604-03 GCAUUCAGACUACCUACUA 
SOCS2 NM_003877 D-017604-04 UCAUAUGUGUCAAAUCCAA 
SOCS3 NM_003955 D-004299-06 CCUAUUACAUCUACUCCGG 
SOCS3 NM_003955 D-004299-08 UCAAGACCUUCAGCUCCAA 
SOCS3 NM_003955 D-004299-21 CAGCAUCUCUGUCGGAAGA 
SOCS3 NM_003955 D-004299-22 GCGAUGGAAUUACCUGGAA 
SOCS4 NM_080867 D-009037-02 GCACAGCUGUUCAUCCAUU 
SOCS4 NM_080867 D-009037-04 GAACUCAUGUUAGAUAAGU 
SOCS4 NM_080867 D-009037-05 ACACGCAGAUUGAUUAUGU 
SOCS4 NM_080867 D-009037-06 GCGCCUGUAUGUUCUUUGA 
SOCS5 NM_014011 D-017374-01 CAACAAAGCAGUCCCUUAA 
SOCS5 NM_014011 D-017374-02 AGACAGAGGUUGCAGGAUA 
SOCS5 NM_014011 D-017374-03 GGAGGAAGCCGUAGUGAAA 
SOCS5 NM_014011 D-017374-04 GAGAGAAGGCGGCUUAGUA 
SOCS6 NM_004232 D-017375-01 GAGGAGACCUGCAUCAAGA 
SOCS6 NM_004232 D-017375-03 GAACAUGUGCCUGUCGUUA 
SOCS6 NM_004232 D-017375-04 GUCCAUAGUUGAUCUAAUU 
SOCS6 NM_004232 D-017375-17 GAUAUGGCCAGCUGCGAUA 
SOCS7 NM_014598 D-027197-01 GGAGAAGUGUGGUUGGUAU 
SOCS7 NM_014598 D-027197-02 AAACCCAAGUUGACAAGAA 
SOCS7 NM_014598 D-027197-03 UCCGAAAGUUCUACUACUA 
SOCS7 NM_014598 D-027197-04 AAGCGCAGCUCAUUUCCAA 
SPSB1 NM_025106 D-015262-01 GGACGACAAGCUCAUCUUU 
SPSB1 NM_025106 D-015262-02 GAACAACAACGACCGAUCG 
SPSB1 NM_025106 D-015262-03 ACUCUGAGCUUCAUUGUGG 
SPSB1 NM_025106 D-015262-04 ACACAACCCUCGUGGGGAA 
SPSB2 NM_032641 D-014947-02 GAACUCUGGGCUACGCUAU 
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SPSB2 NM_032641 D-014947-03 GACCCUCUAUCCGGCAGUA 
SPSB2 NM_032641 D-014947-04 CUACCUGGGCGAAAGGAGA 
SPSB2 NM_032641 D-014947-17 UGACAGUCUGCUACGCAAA 
SPSB3 NM_080861 D-017713-01 GGUCUGGGAUGACUUAAAU 
SPSB3 NM_080861 D-017713-02 GAUGACCUCUCCCGUCUAC 
SPSB3 NM_080861 D-017713-03 ACAAAUACCGCCACACGUU 
SPSB3 NM_080861 D-017713-04 GCGGAGAGGAAGACGAGUA 
SPSB4 NM_080862 D-015283-01 GCAAGAAGCUGUACCCGGU 
SPSB4 NM_080862 D-015283-02 ACACUCAGCUUCAUCGUGG 
SPSB4 NM_080862 D-015283-03 AAAACUAUCUGCAGUACCA 
SPSB4 NM_080862 D-015283-04 GCACCCACGCUGUAGUUGG 
WSB1 NM_134265 D-013015-01 UAUGGGACCUGAAAGAUGA 
WSB1 NM_134265 D-013015-02 GGAAACAUGAUGAAAGUAU 
WSB1 NM_134265 D-013015-03 GAAGUGGUCAGAGAUUUAA 
WSB1 NM_134265 D-013015-04 GAAAACUCCUCCUUAACUU 
WSB2 NM_018639 D-017223-01 CAUGAGGUCCUACACGUUA 
WSB2 NM_018639 D-017223-02 CGAUGUCUCUUGCCUGGUU 
WSB2 NM_018639 D-017223-03 CAAGAUGUCGUGAGAGAUC 
WSB2 NM_018639 D-017223-04 CCGGAAAGCCCUUCGAAGU 
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